β-lactam susceptibility of Escherichia coli isolates from urinary tract infections exhibiting different resistance phenotypes

Revista Espanola de Quimioterapia

Volumn 21, Issue 3, 2008, Pages 149-152

  Lerma, M ^a   Cebrian L ^a   Gimenez M J ^b   Coronel, P ^c   Gimeno, M ^c   Aguilar, L ^b   de Lomas, J García ^d  

^a Instituto Valenciano de Microbiologia   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c Tedec Meiji Farma SA   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

lactamase; Cefditoren; E. coli

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM DERIVATIVE; CEFDITOREN; CEFMINOX; CEFOTAXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; PENICILLINASE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; URINARY TRACT INFECTION;

BETA-LACTAM RESISTANCE; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; URINARY TRACT INFECTIONS;

EID: 55049083790     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int J Antimicrob Agents 2003;22(Suppl. 2):49-52.
2. Alonso Sanz M, Abad Becquer MI. Fenotipos de resistencia en aislamientos urinarios de Escherichia coli en la comunidad: implicaciones terapéuticas. Med Clin (Barc) 2003;120:361-4.
3. Kahlmeter G, ECO.SENS. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003;51:69-76.
4. Rodríguez-Baño J, Navarro MD, Romero L y cols. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42:1089-94.
5. Clinical and Laboratory Standards Institute/NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that growth aerobically; Approved standard M7-A6. CLSI, Wayne, PA, USA, 2003.
6. Clinical and Laboratory Standards Institute/NCCLS. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. CLSI/NCCLS document M100-S15. CLSI, Wayne, PA, USA, 2005.
7. Sanford JP. Urinary Tract Symptoms and Infections. Ann Rev Med 1975;26:485-98.
8. Naber KG. Treatment options for acute uncomplicated cystitis in adults. J Antimicrob Chemother 2000;46(Suppl. 1):23-7.
9. Sadaba B, Azanza JR, Quetglas EG, et al. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study. Rev Esp Quimioter 2007;20:51-60.
10. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-86.